GSK’s New Asthma Medication Demonstrates Potential

In a new test, GSK’s experimental medication reduced the number of asthma episodes, which was the main aim. This is encouraging for the therapy and the British pharmaceutical creators.

According to GSK, the medication known as depemokimab showed “significant and meaningful reductions” in the frequency of asthma episodes in those with eosinophilic asthma.

As per GSK, the medication may be the first long term treatment that is authorised and has a six month dosage regimen for individuals with serious asthma.

GSK’s chief scientific officer stated: “Discovered by our scientists in Stevenage, Depemokimab builds on our deep heritage and leadership in respiratory medicine and has the potential to make a real difference to the millions of people whose lives are affected every day by severe asthma,” said Tony Wood, GSK’s chief scientific officer.